Novus Therapeutics (NASDAQ:NVUS) issued its earnings results on Thursday, March 28th. The biopharmaceutical company reported ($0.49) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.40) by ($0.09), MarketWatch Earnings reports.
Novus Therapeutics stock traded up $0.09 during midday trading on Friday, hitting $4.24. 8,910 shares of the stock were exchanged, compared to its average volume of 11,080. Novus Therapeutics has a 1 year low of $1.52 and a 1 year high of $8.61. The company has a market capitalization of $40.00 million, a price-to-earnings ratio of -2.72 and a beta of 3.54.
A number of equities analysts have recently commented on the stock. Zacks Investment Research downgraded shares of Novus Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, March 30th. ValuEngine raised shares of Novus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd.
Novus Therapeutics Company Profile
Novus Therapeutics, Inc, a pharmaceutical company, focuses on developing products for patients with disorders of ear, nose, and throat. Its lead product is (OP-02), a surfactant-based combination drug product for patients at risk for, or with, otitis media (OM) (middle ear inflammation with or without infection).
Recommended Story: Different Types of Derivatives
Receive News & Ratings for Novus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.